D. Jasinski

发表

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

D. Jasinski, J. Pevnick, J. Griffith, 1978, Archives of general psychiatry.

Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving

Monique Ernst, Albert Gjedde, Hiroto Kuwabara, 2006, Neuropsychopharmacology.

Evaluation of the Abuse Liability of Modafinil and Other Drugs for Excessive Daytime Sleepiness Associated with Narcolepsy

D. Jasinski, R. Kovačević-Ristanović, Ružica Kovačević-Ristanović, 2000, Clinical neuropharmacology.

Abuse liability studies of opioid agonist-antagonists in humans.

K. Preston, D. Jasinski, Donald R. Jasinski, 1991, Drug and alcohol dependence.

Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.

H. Jones, D. Jasinski, Rolley E. Johnson, 2005, Drug and alcohol dependence.

Pharmacologic basis for nicotine replacement.

J. Henningfield, D. Jasinski, 1988, Progress in clinical and biological research.

Effects of (−)Δ9-trans-tetrahydrocannabinol in man

F. Korte, D. Jasinski, H. Isbell, 2004, Psychopharmacologia.

A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

W. Bickel, D. Ciraulo, S. Segal, 2013, JAMA psychiatry.

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

D. Jasinski, P. Mansky, W. Martin, 1973, Archives of general psychiatry.

A comparison of LSD-25 with (−)-Δ9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC

D. Jasinski, H. Isbell, 2004, Psychopharmacologia.

Physiological parameters of morphine dependence in man--tolerance, early abstinence, protracted abstinence.

D. Jasinski, W. Martin, 1969, Journal of psychiatric research.

Abuse liability assessment of atomoxetine in a drug-abusing population.

Rodney J. Moore, D. Jasinski, A. Allen, 2008, Drug and alcohol dependence.

Abuse liability of testosterone

D. Jasinski, J. T. Sullivan, M. Fingerhood, 1997, Journal of psychopharmacology.

5-HT3 receptor antagonism and psychoactivity

K. Preston, D. Jasinski, J. T. Sullivan, 1996, Journal of psychopharmacology.

Rapid physiologic effects of nicotine in humans and selective blockade of behavioral effects by mecamylamine.

D. Jasinski, R. E. Johnson, K. Miyasato, 1983, NIDA research monograph.

Abuse liability assessment in human subjects

J. Henningfield, D. Jasinski, Rolley E. Johnson, 1984 .

Clinical Procedures for the Assessment of Abuse Potential

J. Henningfield, D. Jasinski, Rolley E. Johnson, 1987 .

Intravenous methylphenidate abuse. Prototype for prescription drug abuse.

D. Jasinski, T. Parran, Theodore Vandoren Parran, 1991, Archives of internal medicine.

Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial

H. Kranzler, M. Bohn, R. Anton, 1996, Psychopharmacology.

Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations

E. Sellers, S. Schnoll, R. Weiss, 2007, The Clinical journal of pain.

Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic.

D. Jasinski, D. Rastegar, Jessica L. Colburn, 2012, Journal of opioid management.

A Buprenorphine Stabilization and Rapid‐Taper Protocol for the Detoxification of Opioid‐Dependent Patients

D. Jasinski, T. Parran, C. Adelman, 1994 .

Sublingual versus subcutaneous buprenorphine in opiate abusers

D. Jasinski, R. E. Johnson, P. Fudala, 1989, Clinical pharmacology and therapeutics.

Learning Disabilities in Alcohol-Dependent Adults

D. Jasinski, Sharyn S. Rhodes, 1990, Journal of learning disabilities.

Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study.

H. Jones, D. Jasinski, Rolley E. Johnson, 2006, The American journal on addictions.

Tolerance and dependence to opiates

D. Jasinski, 1997, Acta anaesthesiologica Scandinavica.

Effects of (--)delta-9-trans-tetrahydrocannabinol in man.

F. Korte, D. Jasinski, H. Isbell, 1967, Psychopharmacologia.

Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo.

C. Haertzen, D. Jasinski, R. E. Johnson, 1986, The Journal of pharmacology and experimental therapeutics.

Skin conductance responses to hypercapnia in man during a cycle of addiction to morphine

D. Jasinski, W. Martin, B. E. Jones, 2004, Psychopharmacologia.

REVIEW OF THE EFFECTS IN MAN OF MARIJUANA AND TETRAHYDROCANNABINOLS ON SUBJECTIVE STATE AND PHYSIOLOGIC FUNCTIONING

C. Haertzen, D. Jasinski, H. Isbell, 1971 .

Comparison of intravenously administered methadone, morphine and heroin.

K. Preston, D. Jasinski, Donald R. Jasinski, 1986, Drug and alcohol dependence.

Prevalence of hepatitis C in a chemically dependent population.

D. Jasinski, J. T. Sullivan, M. Fingerhood, 1993, Archives of internal medicine.

Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone

D. Jasinski, J. D. Sapira, W. Martin, 1968, Clinical pharmacology and therapeutics.

Abrupt withdrawal from therapeutically administered diazepam. Report of a case.

C. Haertzen, D. Jasinski, J. Pevnick, 1978, Archives of general psychiatry.

The Use of the Polaroid CU Camera in Pupillography

D. Jasinski, W. Martin, W. G. Marquardt, 1967 .

A comparative assay of nefopam, morphine and d-amphetamine

K. Preston, D. Jasinski, 2004, Psychopharmacology.

Evaluation of tilidine for morphine-like subjective effects and euphoria.

K. Preston, D. Jasinski, Donald R. Jasinski, 1986, Drug and alcohol dependence.

Nicotine: Abuse Liability, Dependence Potential and Pharmacologic Treatment of Dependence

S. Goldberg, J. Henningfield, D. Jasinski, 1987 .

Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.

D. Jasinski, D. Rastegar, M. Fingerhood, 2009, Journal of substance abuse treatment.

A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts

W. Bickel, M. Stitzer, G. Bigelow, 1988, Clinical pharmacology and therapeutics.

Evaluation of nalbuphine for abuse potential

D. Jasinski, P. Mansky, Peter A. Mansky, 1972, Clinical pharmacology and therapeutics.

Buprenorphine Reduces Cerebral Glucose Metabolism in Polydrug Abusers

K. Preston, E. London, R. Dannals, 1994, Neuropsychopharmacology.

Abuse potential and pharmacological comparison of tramadol and morphine.

K. Preston, D. Jasinski, M. Testa, 1991, Drug and alcohol dependence.

Human pharmacology of narcotic antagonists.

D. Jasinski, 1979, British journal of clinical pharmacology.

Quantified human sleep after pentobarbital

D. Jasinski, D. Kay, O. A. Kelly, 1972, Clinical pharmacology and therapeutics.

Assessment of the Dependence Liability of Opiates and Sedative-Hypnotics

D. Jasinski, 1973 .

Catecholamine and 17-hydroxycorticosteroid excretion during a cycle of morphine dependence in man.

J. W. Brooks, D. Jasinski, J. Sloan, 1969, Journal of psychiatric research.

The respiratory effects of morphine during a cycle of dependence.

D. Jasinski, J. D. Sapira, W. Martin, 1968, The Journal of pharmacology and experimental therapeutics.

The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone).

C. Haertzen, D. Jasinski, W. Martin, 1967, The Journal of pharmacology and experimental therapeutics.

Morphine effects on human REM state, waking state and NREM sleep

D. Jasinski, D. Kay, R. B. Eisenstein, 2004, Psychopharmacologia.

Assessment of the Abuse Potential of Narcotic Analgesics in Animals

D. Jasinski, W. Martin, 1977 .

Liver disease in narcotic addicts I. The role of the drug

D. Jasinski, J. D. Sapira, W. Martin, 1968, Clinical pharmacology and therapeutics.

Liver disease in narcotic addicts II. The role of the needle

D. Jasinski, J. D. Sapira, C. Gorodetzky, 1968, Clinical pharmacology and therapeutics.

Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

B. Lester, H. Jones, K. O’grady, 2005, Drug and alcohol dependence.

Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.

B. Lester, H. Jones, N. Haug, 2001, Drug and alcohol dependence.

Dosing Adjustments in Postpartum Patients Maintained on Buprenorphine or Methadone

H. Jones, K. O’grady, D. Jasinski, 2008, Journal of addiction medicine.

Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration.

H. Jones, M. Huestis, D. Jasinski, 2007, Clinical chemistry.

The psychopharmacologic and prolactin response after large doses of naloxone in man

C. Haertzen, D. Jasinski, Rolley E. Johnson, 1988, Pharmacology Biochemistry and Behavior.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations

Jennifer A. Haythornthwaite, Richard W. Foltin, George E. Bigelow, 2012, PAIN®.

Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)

D. Jasinski, D. R. Jasinski, 1977 .

Therapeutic usefulness of propoxyphene napsylate in narcotic addiction.

D. Jasinski, J. Pevnick, J. Griffith, 1977, Archives of general psychiatry.

Studies of the dependence‐producing properties of GPA‐1657, profadol, and propiram in man

R. Hoeldtke, D. Jasinski, W. Martin, 1971, Clinical pharmacology and therapeutics.

Highly active antiretroviral therapy outcomes in a primary care clinic

D. Jasinski, D. Rastegar, M. Fingerhood, 2003, AIDS care.

Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine.

J. Henningfield, D. Jasinski, K. Miyasato, 1985, The Journal of pharmacology and experimental therapeutics.

Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

W K Bickel, W. Bickel, M. Stitzer, 1988, The Journal of pharmacology and experimental therapeutics.

Human abuse liability assessment by measurement of subjective and physiological effects.

J. Henningfield, D. Jasinski, Donald R. Jasinski, 1989, NIDA research monograph.

A comparison of fenfluramine and amphetamine in man

J. Nutt, D. Jasinski, J. Griffith, 1975, Clinical pharmacology and therapeutics.

The Assessment of the Abuse Potentiality of Sedative/Hypnotics (Depressants) (Methods Used in Animals and Man)

D. Jasinski, H. F. Fraser, 1977 .

Cigarette smokers self-administer intravenous nicotine

J. Henningfield, D. Jasinski, K. Miyasato, 1983, Pharmacology Biochemistry and Behavior.

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

D. Jasinski, S. Krishnan, 2009, Journal of psychopharmacology.

An evaluation of the abuse potential of modafinil using methylphenidate as a reference

D. Jasinski, 2000, Journal of psychopharmacology.

Psychoactivity and abuse potential of sumatriptan

K. Preston, D. Jasinski, J. T. Sullivan, 1992, Clinical pharmacology and therapeutics.

History of abuse liability testing in humans.

D. Jasinski, 1991, British journal of addiction.

Clonidine in morphine withdrawal. Differential effects on signs and symptoms.

D. Jasinski, R. E. Johnson, Rolley E. Johnson, 1985, Archives of general psychiatry.

Electroencephalographic and behavioral correlates of buprenorphine administration

S. Lukas, D. Jasinski, Rolley E. Johnson, 1984, Clinical pharmacology and therapy.

Progress report of the NIDA Addiction Research Center.

J. Henningfield, C. Haertzen, D. Jasinski, 1982, NIDA research monograph.

Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects.

K. Preston, D. Jasinski, 1986, Drug and alcohol dependence.

Progress report of the NIDA Addiction Research Center, Baltimore, Maryland, 1982.

J. Henningfield, D. Jasinski, J. E. Hickey, 1983, NIDA research monograph.

Lithium: effects on subjective functioning and morphine-induced euphoria.

J. Nutt, W. Bunney, C. Haertzen, 1977, Science.

Stimulus control and drug dependence.

D. Jasinski, 1981, NIDA research monograph.

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

D. Jasinski, S. Krishnan, 2009, Journal of psychopharmacology.

Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol

D. Epstein, K. Preston, D. Jasinski, 2006, Biological Psychology.

Abuse potential of oral tramadol

K. Preston, D. Jasinski, J. T. Sullivan, 1993 .

Effects of diethylpropion and d‐amphetamine after subcutaneous and oral administration

D. Jasinski, J. Griffith, J. G. Nutt, 1974, Clinical pharmacology and therapeutics.

Effects of tramadol in humans: assessment of its abuse potential.

K. Preston, D. Jasinski, 1989, NIDA research monograph.

Assessment of dezocine for morphine‐like subjective effects and miosis

K. Preston, D. Jasinski, 1985, Clinical pharmacology and therapeutics.

Effects of short‐ and long‐term administration of pentazocine in man

R. Hoeldtke, D. Jasinski, W. Martin, 1970, Clinical pharmacology and therapeutics.

Methadone--a reevaluation.

C. Haertzen, D. Jasinski, P. Mansky, 1973, Archives of general psychiatry.

Comparison of drug treatment histories of single and multiple drug abusers in detox.

D. Jasinski, S. Greberman, 2001, Addictive behaviors.

Abuse potential of morphine/dextromethorphan combinations.

D. Jasinski, 2000, Journal of pain and symptom management.

Abstinence incentive effects in a short-term outpatient detoxification program.

H. Jones, M. Stitzer, D. Jasinski, 2004, Experimental and clinical psychopharmacology.

ONE-, THREE-, AND SIX-MONTH OUTCOMES AFTER BRIEF INPATIENT OPIOID DETOXIFICATION

M. Stitzer, D. Jasinski, M. Fingerhood, 2001, The American journal of drug and alcohol abuse.

Five-Year Outcomes of a Cohort of HIV-Infected Injection Drug Users in a Primary Care Practice

D. Jasinski, D. Rastegar, M. Fingerhood, 2006, Journal of addictive diseases.

Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users.

K. Preston, R. Wise, D. Jasinski, 1997, The American journal of medicine.

Differential Effects on Signs and Symptoms

D. Jasinski, Rolley E. Johnson, T. Kocher, 2015 .

Human studies of the behavioral pharmacological determinants of nicotine dependence.

R. Herning, S. Lukas, S. Goldberg, 1986, NIDA research monograph.

Investigation of the abuse liability of buspirone in alcohol-dependent patients.

D. Jasinski, J. Griffith, G. R. Mckinney, 1986, The American journal of medicine.

Abuse potential of zomepirac

D. Jasinski, Rolley E. Johnson, T. Kocher, 1983, Clinical pharmacology and therapeutics.

Conceptual basis of replacement therapies for chemical dependence.

J. Henningfield, D. Jasinski, 1988, Progress in clinical and biological research.

Development and Preliminary Experience with an Ease of Extractability Rating System for Prescription Opioids

S. Butler, C. Benoit, S. Budman, 2006, Drug development and industrial pharmacy.

Methadone‐naloxone mixtures for use in methadone maintenance programs; I. An evaluation in man of their pharmacological feasibility; II. Demonstration of acute physical dependence

J. Nutt, D. Jasinski, 1974, Clinical pharmacology and therapeutics.

Psychopharmacology and abuse potential of transnasal butorphanol.

K. Preston, D. Jasinski, J. T. Sullivan, 1994, Drug and alcohol dependence.

Evaluation of a new photographic method for assessing pupil diameters

D. Jasinski, W. Martin, 1967, Clinical pharmacology and therapeutics.

Interdisciplinary studies on phencyclidine at the Addiction Research Center, Lexington, Kentucky [proceedings].

R. Mcquinn, T. Su, E. Cone, 1980, Psychopharmacology bulletin.

Azidomorphine: Subjective effects and suppression of morphine abstinence

D. Jasinski, J. Pevnick, J. Griffith, 1976, Clinical pharmacology and therapy.

Diuretic action of the narcotic antagonist oxilorphan

D. Jasinski, J. G. Nutt, 1974, Clinical pharmacology and therapeutics.

Human pharmacology and abuse potential of meptazinol

D. Jasinski, Rolley E. Johnson, 1987, Clinical pharmacology and therapeutics.

INTRODUCTORY REMARKS

D. Jasinski, 1978 .

Etorphine in man. I. Subjective effects and suppression of morphine abstinence

D. Jasinski, J. Griffith, Carter B. Carr, 1975, Clinical pharmacology and therapeutics.

Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving

Monique Ernst, Albert Gjedde, Jae Sung Lee, 2007, Neuropsychopharmacology.

A Comparison of Clonidine and Buprenorphine in the Outpatient Treatment of Opiate Withdrawal

D. Jasinski, M. Fingerhood, M. Thompson, 2001, Substance abuse.

l-alpha-Acetylmethadol, l-alpha-acetyl-N-normethadol and l-alpha-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog.

D. B. Vaupel, D. Jasinski, 1997, Journal of Pharmacology and Experimental Therapeutics.

Differential effects of μ and κ opioid analgesics on cerebral glucose utilization in the rat

E. London, D. Jasinski, M. Szikszay, 1987, Brain Research.

Short communication Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes

B. Lester, H. Jones, N. Haug, 2001 .

Progress report from the NIDA Addiction Research Center, Baltimore, Maryland.

S. Lukas, J. Henningfield, D. Jasinski, 1984, NIDA research monograph.

An analysis of naltrexone precipitated abstinence in morphine-dependent chronic spinal dogs.

D. Jasinski, W. Martin, C. D. Martin, 1987, The Journal of pharmacology and experimental therapeutics.

Cerebral glucose utilization in human heroin addicts: Case reports from a positron emission tomographic study

J. Links, E. Broussolle, E. London, 1989 .

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

D. Jasinski, W. R. Martin, J. Sloan, 1971, Clinical pharmacology and therapeutics.

OPIATE WITHDRAWAL SYNDROME: ACUTE AND PROTRACTED ASPECTS

D. Jasinski, 1981, Annals of the New York Academy of Sciences.

The clinical pharmacology of pentazocine and tripelennamine (T's and Blues).

D. Jasinski, W. Lange, 1986, Advances in alcohol & substance abuse.

Firing Patterns of Hypothalamic Supraoptic Neurons during Water Deprivation in Monkeys

H. L. Williams, J. D. Coulter, D. Goodenough, 1974, Science.

A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

W. Bickel, D. Ciraulo, S. Segal, 2013, JAMA psychiatry.